337.20
337.20 (0%)
As of Feb 14, 2025
Madrigal Pharmaceuticals, Inc. [MDGL]
Source:
Company Overview
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (“MASH”), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure and premature mortality.
| Country | United States |
| Headquarters | west conshohocken, pennsylvania |
| Phone Number | 404-380-9263 |
| Industry | manufacturing |
| CEO | William J. Sibold |
| Website | www.madrigalpharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $180.1 |
| Operating Profit | $-497.9 |
| Net Income | $-465.9 |
| Net Cash | $5.1 |
Profit Ratios
| Gross Margin | $173.9 |
| Operating Margin | -276.4 |
| Profit as % of Revenues | -37.3% |
| Profit as % of Assets | -55.4% |
| Profit as % of Stockholder Equity | -61.8% |
Management Effectiveness
| Return on Equity | -61.8% |
| Return on Assets | -44.7% |
| Turnover Ratio | 21.4% |
| EBITA | $-497.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,042.2 |
| Total Liabilities | $287.9 |
| Operating Cash Flow | $-455.6 |
| Investing Cash Flow | $-274.4 |
| Financing Cash Flow | $735.1 |
